AI needs patient-level data to be ‘clinically useful’: study

Artificial intelligence for identifying drug-drug interactions (DDIs) remains at an “early stage” of translational readiness, scoping review finds Artificial intelligence (AI) for identifying DDIs has achieved “substantial” methodological development, a review has found, but remains at an early stage of readiness when it comes to translating this to real patient harm risk. The scoping review,